The recent study by Mayo AK et al. evaluates Obeticholic Acid liver safety in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Although the FDA approved Obeticholic acid (OCA) for primary biliary cholangitis in 2016, they recently rejected it for the treatment of MASLD. This regulatory decision stemmed from significant liver safety concerns that emerged during clinical trials. To understand these risks, researchers employed the DILIsym model to simulate OCA's toxicological profile in virtual patient populations.

The research team utilized physiologically based pharmacokinetic (PBPK) modeling to estimate drug exposures in the liver, gut, and plasma. Interestingly, virtual MASLD patients showed significantly higher exposures compared to healthy individuals. Furthermore, the model integrated critical mechanisms such as bile acid transporter inhibition and mitochondrial dysfunction. These specific factors directly contribute to elevations in liver biomarkers, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Predicting Obeticholic Acid Liver Safety via DILIsym

The DILIsym simulations accurately mirrored the liver injury patterns observed in real-world clinical subjects. Specifically, the model showed that bile acid transporter inhibition alone could trigger biomarker elevations similar to those seen in clinical trials. In contrast, mitochondrial uncoupling only caused significant damage at extremely high doses. Therefore, the study confirms that predictive modeling can effectively identify hepatotoxicity risks before late-stage clinical failures occur.

In conclusion, these findings explain the regulatory hurdles that led to the withdrawal of OCA from the US market for MASLD. For the medical community, this research highlights the necessity of precise dosing and rigorous safety monitoring in steatotic liver disease. Moving forward, Quantitative Systems Toxicology (QST) models will likely play a vital role in drug development for complex metabolic conditions. Consequently, these tools help ensure that only the safest therapies reach the bedside.

Frequently Asked Questions

Why was Obeticholic Acid rejected for MASLD?

The FDA rejected Obeticholic Acid for MASLD treatment primarily due to liver safety concerns. Clinical trials revealed significant elevations in liver biomarkers and an increased risk of drug-induced liver injury in this specific patient population.

How does the DILIsym model predict hepatotoxicity?

DILIsym is a Quantitative Systems Toxicology model. It integrates pharmacokinetic data with mechanistic pathways, such as bile acid transport and mitochondrial function, to simulate how a drug affects liver health in different populations.

What are the primary mechanisms of OCA-induced liver injury?

The primary mechanism identified is the inhibition of bile acid transporters. This causes a toxic accumulation of bile acids within the liver. At very high doses, mitochondrial dysfunction also contributes to the injury.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Mayo AK et al. Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Pharmacol Ther. 2026 Jun 22. doi: 10.1002/cpt.70355. PMID: 42332345.

Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-2196.

U.S. Food and Drug Administration. FDA Integrated Review: Obeticholic Acid for Treatment of Pre-cirrhotic NASH with Liver Fibrosis. 2023.